patients with pulmonary hypertension and give them hope for recovery
Consultant Chest Diseases and President of the Saudi Society of Pulmonary Hypertension, Dr. Magdy Muhammad Idris, confirmed that the Saudi Food and Drug Authority has approved Riociguat as the first drug for treating patients with chronic obstructive pulmonary hypertension, which cannot be treated surgically, or in which the patient is repeatedly infected. Or continue after surgery .. The drug has also been approved for the treatment of pulmonary arterial hypertension, which is another type of pulmonary hypertension, thus, riosiguat becomes the only drug approved for treating two types of pulmonary hypertension, and indicated that riosiguat has been developed and introduced in Global strategic cooperation framework with MSD, through one of its subsidiaries, in the control of soluble cyclic guanylate catalysts. MSD is known as Merck in the United States and Canada. He pointed out that chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension are rare types of pulmonary hypertension, which is one of the serious diseases that It affects the lungs and the heart and develops to change the patient’s life and also threatens him with death. It is estimated that chronic thrombotic obstructive pulmonary hypertension affects 1500-2000 people in the Kingdom, while pulmonary arterial hypertension affects 1000-1500 people, as patients develop high blood pressure in the lung arteries What causes them to have difficulty breathing and extreme fatigue and hinders their ability to work and practice daily activities such as walking short distances or climbing stairs, and the President of the Saudi Society for Hypertension of the Pulmonary Artery revealed the results of the important clinical study "CHEST-1" which showed that Riosiguat is the first and only drug Which has achieved significant clinical improvement in COPD patients that cannot be treated surgically, have recurrent or persist after surgery. Riociguat improved patients'' ability to endure exercise, which was demonstrated by assessing the six-minute walking test, revealing an improvement in their ability to walk a longer distance. This came during the scientific and introductory symposium on the drug that was held the day before yesterday in Jeddah, which included many scientific lectures presented by professors and specialists from different countries of the world who dealt with the introduction of the drug and its side effects in addition to its therapeutic effect on patients suffering from chronic pulmonary artery pressure hypertension and the extent of benefits The curative effect of this drug.
Idris assured that patients with pulmonary arterial hypertension will have new hope for recovery from this disease, which is considered the silent killer, as the Food and Drug Administration has authorized this drug, especially for patients with chronic obstructive pulmonary hypertension who have not had any drug treatment options so far if they are Their injury cannot be treated with surgical intervention or if it recurs or persists after surgery. Pulmonary hypertension is a devastating diagnosis, and its symptoms of difficulty breathing, dizziness and fainting weaken the patient’s body. Therefore, the availability of new treatment options achieves a significant clinical improvement and enables patients to perform The daily activities that we do automatically, is a big step forward.
